Articles by Daniel Carlat, MD

Fact Sheet

Supportive Therapy in an Inpatient Psychiatric Hospital

April 17, 2026

Daniel Carlat, MD and Victoria Hendrick, MD

Dr. Hendrick and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Supportive therapy is a psychotherapeutic approach focused on providing emotional and practical support and strengthening a patient's coping mechanisms.

Fact Sheet

Coding and Billing Protocols

April 17, 2026

Daniel Carlat, MD and Victoria Hendrick, MD

Dr. Hendrick and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Coding inpatient psychiatric visits is a way of briefly describing how much work you did and therefore how much money the insurance company should pay for the visit.

A Dangerous Myth in Child Psychiatry

April 11, 2026

Daniel Carlat, MD

Autism doesn't protect against suicide. It hides it.

The Side Effects that Quietly Destroy Teeth

April 3, 2026

Daniel Carlat, MD

It's easy to treat xerostomia as a nuisance, low on the priority list when you're managing psychosis or depression. But left unaddressed, it quietly does real damage.

The Anxiety Treatment Most U.S. Clinicians Haven’t Heard Of

March 28, 2026

Daniel Carlat, MD

A German medication beat paroxetine for anxiety. Its approved in 20 countries. Most U.S. clinicians have never heard of it.

Depression Rarely Travels Alone

March 7, 2026

Daniel Carlat, MD

We tend to blame the meds.

But what if the real reason a patient isn’t improving… is because we’re treating the wrong thing?

Rapid-acting Medications

February 28, 2026

Daniel Carlat, MD

There are times in treatment when the usual pace just won’t do. That’s when we reach for rapid-acting medications.

Difficult-to-Treat Depression

February 19, 2026

Daniel Carlat, MD

Depression distorts memory. Measurement restores it.

Flow Device: FDA Approval vs Real-World Effectivenes

February 9, 2026

Daniel Carlat, MD

In December 2025, Flow did in fact receive FDA Approval, based on data from the Empower trial. Before that, it had been marketed under FDA clearance—a lower evidentiary bar. That correction matters—and it sharpens the question many subscribers have been asking me: How much does FDA approval tell us about real‑world effectiveness?